Nkarta, Inc. (NASDAQ:NKTX) Receives $15.00 Average Price Target from Analysts

Nkarta, Inc. (NASDAQ:NKTX) has earned an average recommendation of “Buy” from the seven analysts that are currently covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $15.00.

A number of equities research analysts recently issued reports on the stock. Mizuho decreased their price target on shares of Nkarta from $20.00 to $16.00 and set an “outperform” rating on the stock in a research note on Thursday, November 21st. HC Wainwright decreased their target price on shares of Nkarta from $22.00 to $18.00 and set a “buy” rating on the stock in a research report on Monday, November 11th. RODMAN&RENSHAW upgraded Nkarta to a “strong-buy” rating in a research report on Wednesday, October 9th. Rodman & Renshaw began coverage on Nkarta in a research report on Wednesday, October 9th. They set a “buy” rating and a $14.00 price objective on the stock. Finally, Needham & Company LLC dropped their target price on Nkarta from $13.00 to $11.00 and set a “buy” rating for the company in a report on Friday, November 8th.

Nkarta Trading Down 6.0 %

Shares of Nkarta stock opened at $2.35 on Monday. The firm has a market cap of $165.84 million, a PE ratio of -1.25 and a beta of 0.82. The stock has a 50 day moving average of $2.91 and a 200 day moving average of $4.59. Nkarta has a 12 month low of $2.08 and a 12 month high of $16.24.

Institutional Trading of Nkarta

Several institutional investors have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. purchased a new stake in shares of Nkarta in the second quarter worth approximately $26,000. Erste Asset Management GmbH bought a new position in Nkarta in the 3rd quarter valued at $33,000. GAMMA Investing LLC grew its position in Nkarta by 110.9% in the 3rd quarter. GAMMA Investing LLC now owns 9,972 shares of the company’s stock valued at $45,000 after acquiring an additional 5,243 shares during the last quarter. Forefront Analytics LLC purchased a new stake in Nkarta in the second quarter worth $70,000. Finally, Intech Investment Management LLC bought a new stake in shares of Nkarta during the third quarter worth $74,000. Institutional investors own 80.54% of the company’s stock.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.